#BEGIN_DRUGCARD DB00992

# AHFS_Codes:
Not Available

# ATC_Codes:
L01XD03

# Absorption:
In vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Metvix

# CAS_Registry_Number:
33320-16-0

# ChEBI_ID:
724125

# Chemical_Formula:
C6H11NO3

# Chemical_IUPAC_Name:
methyl 5-amino-4-oxopentanoate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.

# Dosage_Forms:
Not Available

# Drug_Category:
Antineoplastic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
19592269	Smits T, Moor AC: New aspects in photodynamic therapy of actinic keratoses. J Photochem Photobiol B. 2009 Sep 4;96(3):159-69. Epub 2009 Jun 13.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.2

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Freely soluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Methyl aminolevulinate

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3

# InChI_Key:
InChIKey=YUUAYBAIHCDHHD-UHFFFAOYSA-N

# Indication:
For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
992

# Mechanism_Of_Action:
Photosensitization following application of methyl aminolevulinate cream occurs through the metabolic conversion of methyl aminolevulinate (prodrug) to photoactive porphyrins (PAP), which accumulates in the skin lesions to which the cream has been applied. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoactive porphyrins to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
145.1564

# Molecular_Weight_Mono:
145.073893223

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164784028

# Pharmacology:
After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.

# Predicted_LogP_Hydrophobicity:
-1.3

# Predicted_LogS:
0.18

# Predicted_Water_Solubility:
2.20e+02 g/l

# Primary_Accession_No:
DB00992

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
157922

# PubChem_Substance_ID:
46507004

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD01105

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC(=O)CCC(=O)CN

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
5-Aminolevulinic acid methyl ester
Aminolevulinic acid methyl ester

# Synthesis_Reference:
Not Available

# Toxicity:
The severity of local phototoxic reactions such as erythema, pain and burning sensation may increase in case of prolonged application time or very high light intensity.

# Update_Date:
2013-02-08 16:19:49 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Methyl_aminolevulinate

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
FCGR1A

# Drug_Target_1_GenBank_ID_Gene:
X14356

# Drug_Target_1_GenBank_ID_Protein:
31332

# Drug_Target_1_GeneCard_ID:
FCGR1A

# Drug_Target_1_Gene_Name:
FCGR1A

# Drug_Target_1_Gene_Sequence:
>1125 bp
ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
AAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC
CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG

# Drug_Target_1_General_Function:
Involved in receptor signaling protein activity

# Drug_Target_1_General_References:
1379234	Ernst LK, van de Winkel JG, Chiu IM, Anderson CL: Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products. J Biol Chem. 1992 Aug 5;267(22):15692-700.
1402657	Benech PD, Sastry K, Iyer RR, Eichbaum QG, Raveh DP, Ezekowitz RA: Definition of interferon gamma-response elements in a novel human Fc gamma receptor gene (Fc gamma RIb) and characterization of the gene structure. J Exp Med. 1992 Oct 1;176(4):1115-23.
1430234	Porges AJ, Redecha PB, Doebele R, Pan LC, Salmon JE, Kimberly RP: Novel Fc gamma receptor I family gene products in human mononuclear cells. J Clin Invest. 1992 Nov;90(5):2102-9.
2911749	Allen JM, Seed B: Isolation and expression of functional high-affinity Fc receptor complementary DNAs. Science. 1989 Jan 20;243(4889):378-81.
2974947	Allen JM, Seed B: Nucleotide sequence of three cDNAs for the human high affinity Fc receptor (FcRI). Nucleic Acids Res. 1988 Dec 23;16(24):11824.

# Drug_Target_1_HGNC_ID:
HGNC:3613

# Drug_Target_1_HPRD_ID:
00904

# Drug_Target_1_ID:
784

# Drug_Target_1_Locus:
1q21.2-q21.3

# Drug_Target_1_Molecular_Weight:
42632

# Drug_Target_1_Name:
High affinity immunoglobulin gamma Fc receptor I

# Drug_Target_1_Number_of_Residues:
374

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00047	ig

# Drug_Target_1_Protein_Sequence:
>High affinity immunoglobulin gamma Fc receptor I precursor
MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
LQEGVHRKEPQGAT

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-15

# Drug_Target_1_Specific_Function:
Binds to the Fc region of immunoglobulins gamma. High affinity receptor

# Drug_Target_1_SwissProt_ID:
P12314

# Drug_Target_1_SwissProt_Name:
FCGR1_HUMAN

# Drug_Target_1_Synonyms:
CD64 antigen
Fc-gamma RI
FcRI
High affinity immunoglobulin gamma Fc receptor I precursor
IgG Fc receptor I

# Drug_Target_1_Theoretical_pI:
8.08

# Drug_Target_1_Transmembrane_Regions:
293-313

#END_DRUGCARD DB00992
